Molecular profiling can help inform treatment decisions for ovarian cancer patients. Tumor profiles are discovered by testing the tumor for biomarkers, such as PD-L1, homologous recombination deficiency (HRD), tumor mutation burden (TMB), and microsatellite instability (MSI) and using next generation sequencing to identify genomic alterations in more than 300 genes. By identifying the altered cellular pathways in a patient’s tumor, the tumor profile can help prioritize the treatments most likely to be effective.
Clearity’s Tumor Profiling Report matches the biomarkers and unique mutations in each patient’s cancer to the most suitable treatments. We summarize the molecular profiling results from any lab you choose in one easy-to-read interpretive report, which is accessible online and provides information on biomarkers, clinical evidence, matching therapies and clinical trials. The results point to NCCN-recommended standard of care drugs, drugs approved in other indications or investigational agents in clinical trials that may provide clinical benefit.